Early identification of cardiovascular risk using genomics and proteomics

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Coronary heart disease (CHD) will soon become the leading cause of death and morbidity in the world. Early detection and treatment of CHD is thus imperative to improve global health. Atherosclerosis of the coronary arteries is a complex multifactorial disease process involving multiple pathways that can be influenced by both genetic and environmental factors. With the recent advances in genomics and proteomics, many new risk factors with small-to-moderate effects are likely to be identified. Additionally, individualized risk stratification and targeted therapy may become feasible; each individual could potentially be assessed with a panel of tests for genomic and proteomic markers and, on the basis of the individual's composite risk profile, preventive and therapeutic steps could then be undertaken. With a multimarker approach, it may also be possible to identify alterations in pathways involved in atherogenesis, rather than focus on individual risk factors. In this article, we use the specific example of atherosclerosis to discuss the role of genomics and proteomics in cardiovascular risk assessment.

Original languageEnglish (US)
Pages (from-to)309-317
Number of pages9
JournalNature Reviews Cardiology
Volume7
Issue number6
DOIs
StatePublished - Jun 2010

Fingerprint

Genomics
Proteomics
Atherosclerosis
Coronary Disease
Cause of Death
Coronary Vessels
Morbidity
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Early identification of cardiovascular risk using genomics and proteomics. / Kullo, Iftikhar Jan; Cooper, Leslie T Jr.

In: Nature Reviews Cardiology, Vol. 7, No. 6, 06.2010, p. 309-317.

Research output: Contribution to journalArticle

@article{ee9a3d3f6af0435d91bc8a23383e191d,
title = "Early identification of cardiovascular risk using genomics and proteomics",
abstract = "Coronary heart disease (CHD) will soon become the leading cause of death and morbidity in the world. Early detection and treatment of CHD is thus imperative to improve global health. Atherosclerosis of the coronary arteries is a complex multifactorial disease process involving multiple pathways that can be influenced by both genetic and environmental factors. With the recent advances in genomics and proteomics, many new risk factors with small-to-moderate effects are likely to be identified. Additionally, individualized risk stratification and targeted therapy may become feasible; each individual could potentially be assessed with a panel of tests for genomic and proteomic markers and, on the basis of the individual's composite risk profile, preventive and therapeutic steps could then be undertaken. With a multimarker approach, it may also be possible to identify alterations in pathways involved in atherogenesis, rather than focus on individual risk factors. In this article, we use the specific example of atherosclerosis to discuss the role of genomics and proteomics in cardiovascular risk assessment.",
author = "Kullo, {Iftikhar Jan} and Cooper, {Leslie T Jr.}",
year = "2010",
month = "6",
doi = "10.1038/nrcardio.2010.53",
language = "English (US)",
volume = "7",
pages = "309--317",
journal = "Nature Reviews Cardiology",
issn = "1759-5002",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Early identification of cardiovascular risk using genomics and proteomics

AU - Kullo, Iftikhar Jan

AU - Cooper, Leslie T Jr.

PY - 2010/6

Y1 - 2010/6

N2 - Coronary heart disease (CHD) will soon become the leading cause of death and morbidity in the world. Early detection and treatment of CHD is thus imperative to improve global health. Atherosclerosis of the coronary arteries is a complex multifactorial disease process involving multiple pathways that can be influenced by both genetic and environmental factors. With the recent advances in genomics and proteomics, many new risk factors with small-to-moderate effects are likely to be identified. Additionally, individualized risk stratification and targeted therapy may become feasible; each individual could potentially be assessed with a panel of tests for genomic and proteomic markers and, on the basis of the individual's composite risk profile, preventive and therapeutic steps could then be undertaken. With a multimarker approach, it may also be possible to identify alterations in pathways involved in atherogenesis, rather than focus on individual risk factors. In this article, we use the specific example of atherosclerosis to discuss the role of genomics and proteomics in cardiovascular risk assessment.

AB - Coronary heart disease (CHD) will soon become the leading cause of death and morbidity in the world. Early detection and treatment of CHD is thus imperative to improve global health. Atherosclerosis of the coronary arteries is a complex multifactorial disease process involving multiple pathways that can be influenced by both genetic and environmental factors. With the recent advances in genomics and proteomics, many new risk factors with small-to-moderate effects are likely to be identified. Additionally, individualized risk stratification and targeted therapy may become feasible; each individual could potentially be assessed with a panel of tests for genomic and proteomic markers and, on the basis of the individual's composite risk profile, preventive and therapeutic steps could then be undertaken. With a multimarker approach, it may also be possible to identify alterations in pathways involved in atherogenesis, rather than focus on individual risk factors. In this article, we use the specific example of atherosclerosis to discuss the role of genomics and proteomics in cardiovascular risk assessment.

UR - http://www.scopus.com/inward/record.url?scp=77953578271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953578271&partnerID=8YFLogxK

U2 - 10.1038/nrcardio.2010.53

DO - 10.1038/nrcardio.2010.53

M3 - Article

C2 - 20440292

AN - SCOPUS:77953578271

VL - 7

SP - 309

EP - 317

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

SN - 1759-5002

IS - 6

ER -